Tarsus Pharmaceuticals to Engage at Key Investor Events Soon

Tarsus Pharmaceuticals to Engage with Investors at Upcoming Conferences

IRVINE, Calif. — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has exciting news for investors and stakeholders as it reveals plans to participate in several key investor conferences in the near future. These events present a golden opportunity for the team to share their latest advancements and discuss their ambitious goals in the pharmaceutical sector.

Details of Upcoming Conferences

The first of these events is the Wells Fargo 20th Annual Healthcare Conference, scheduled for Wednesday, September 3rd, at 6:30 a.m. PT / 9:30 a.m. ET. Shortly after, the company will take part in the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9th, at 7:30 a.m. PT / 10:30 a.m. ET. These appearances are particularly crucial as they will allow Tarsus to share insights into their innovative pipeline aimed at addressing unmet medical needs.

Accessing Live Webcasts

For those interested in catching live webcasts of these events, Tarsus will provide access through the events section on their website. This arrangement ensures that both investors and interested parties can engage with the content and keep abreast of the latest developments. Additionally, Tarsus plans to archive replays of these presentations within 48 hours for a limited time, allowing more flexibility for viewers who might miss the live sessions.

Innovations at Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is at the forefront of using proven science and innovative technology to transform healthcare, with a focal point on eye care. The company is dedicated to developing treatments that address serious health issues, particularly in the realms of ophthalmology and infectious diseases. Currently, one of its flagship products, XDEMVY (lotilaner ophthalmic solution) 0.25%, has gained FDA approval in the United States for the treatment of Demodex blepharitis, marking a significant milestone in Tarsus's commitment to enhancing patient care.

Pipeline Products in Development

In addition to XDEMVY, Tarsus is actively working on several promising candidates to widen its therapeutic offerings. TP-04 is being developed as an ophthalmic gel for potential treatment options for Ocular Rosacea, while TP-05 is an oral tablet in the pipeline intended to prevent Lyme disease. This robust pipeline reflects Tarsus's strategic focus on tackling high unmet medical needs across various health segments.

Contact Information for Media and Investors

Those who wish to reach out for more information can contact the media team at Tarsus Pharmaceuticals. Adrienne Kemp, Sr. Director of Corporate Communications, is available at (949) 922-0801 or via email at AKemp@tarsusrx.com. The investor relations inquiries can be directed towards David Nakasone, Head of Investor Relations, at (949) 620-3223 or through email at DNakasone@tarsusrx.com. These points of contact are essential for investors looking to gain insight into Tarsus's future directions and the potential impacts on their investments.

Frequently Asked Questions

What conferences will Tarsus Pharmaceuticals be attending?

Tarsus will participate in the Wells Fargo 20th Annual Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference.

Where can I watch the presentations from the conferences?

Live webcasts of the presentations can be accessed on the Tarsus Pharmaceuticals website, with replays also available afterward.

What is the main focus of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals focuses on advancing treatments primarily in eye care and infectious disease prevention, addressing significant unmet medical needs.

What are Tarsus Pharmaceuticals' notable products?

One flagship product is XDEMVY, an FDA-approved treatment for Demodex blepharitis. The company is also developing TP-04 and TP-05 for other conditions.

How can I contact Tarsus Pharmaceuticals for more information?

Media inquiries can be directed to Adrienne Kemp, and investor relations inquiries can be sent to David Nakasone through their provided contact information.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.